We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.
|Bid||0.0350 x 0|
|Ask||0.0450 x 0|
|Day's Range||0.0400 - 0.0450|
|52 Week Range||0.0350 - 0.1650|
|Beta (5Y Monthly)||3.00|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 28, 2023 - Dec 04, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Toronto, Ontario--(Newsfile Corp. - November 17, 2023) - Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF) ("Khiron" or the "Company") is pleased to announce that the Company has completed the sale of its European subsidiaries, being Khiron Europe GmbH ("Khiron Europe"), Zerenia Clinics Limited ("Zerenia UK"), PharmaDrug Production GmbH ("Pharmadrug"), Khiron Life Sciences UK Limited ("Khiron UK") and Khiron Life Sciences Spain SL ("Khiron Spain", and collectively with Khiron Europe, Zereni
Toronto, Ontario--(Newsfile Corp. - November 16, 2023) - Khiron Life Sciences Corp. (TSXV: KHRN) (OTC Pink: KHRNF) ("Khiron" or the "Company") today announced that the Company and 2518542 Alberta Ltd., a company controlled by Avonlea Drewry Holdings Inc. (the "Purchaser"), have entered into an amended and restated share purchase agreement (the "Restated Purchase Agreement") dated November 15, 2023, providing for the purchase and sale of the Company's European subsidiaries. Under the terms of the
Toronto, Ontario--(Newsfile Corp. - June 5, 2023) - Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQB: KHRNF) ("Khiron" or the "Company") announced today that the Company has agreed to a $500,000 non-interesting bearing refundable deposit from 2518542 Alberta Ltd. ("251"), a company controlled by Avonlea-Drewry Holdings Inc., to be secured by all of Khiron's present and after-acquired property pursuant to a general security agreement and a pledge of Khiron's shares in its subsidiaries, Pharmadrug P
Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) announced today that, further to its press release dated April 17, 2023, the Ontario Securities Commission (the "OSC") has denied the Company's application for a management cease trade order (the "MCTO") in connection with its delay in filing its audited annual financial statements (the "Financial Statements"), management's discussion and analysis ("MD&A") and related Chief Executive Officer and Chief Financial Of
On 16 March 2023, after five years of observational data collection the German Federal Joint Committee (G-BA) decided on the future regulations that will govern the prescription of medical cannabis as a benefit of the statutory health insuranceAfter several months of discussions and thoroughly analyzing the data, the G-BA passed regulations that ensure patient care with medical cannabis and coverage by statutory health insuranceGermany is the largest and fastest growing medical cannabis market i
First phase of optimization was focused on streamlining Colombian operations, resulting in a moving forward annualized cost reduction of CAD 5.0 million, representing overall cost savings of more than 45% compared to 20221.Khiron has completed the wind down of its Colombian cultivation and extraction activities, to focus on its clinics business and its high-margin B2C medical cannabis model in Colombia.Similar to the Company’s European production model, Khiron Colombia will outsource the product
Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) is pleased announce that it has appointed Mr. Michael O'Connor as Chief Financial Officer of the Company, replacing the Company's CFO, Ms. Helen Bellwood.
To the annoyance of some shareholders, Khiron Life Sciences Corp. ( CVE:KHRN ) shares are down a considerable 47% in...
Toronto, Ontario--(Newsfile Corp. - April 4, 2023) - Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQB: KHRNF) ("Khiron" or the "Company") is pleased to announce that it has closed today its previously announced marketed public offering of units of the Company ("Units"), including the exercise in full of the over-allotment option (the "Offering").A total of 13,800,000 Units were sold at a price of $0.05 per Unit (the "Offering Price") for aggregate gross proceeds of $690,000. ...
500 Burrard Street
Vancouver, BC V6C 2B5
Industry: Drug Manufacturers - Specialty & Generic
Full Time Employees:
Khiron Life Sciences Corp. operates as an integrated medical and cannabis company in Latin America and Europe. It operates through Health Services, Medical Cannabis Products, and Wellbeing Products segments. The company focuses on the cultivation, production, distribution, and export of tetrahydrocannabinol and cannabidiol (CBD) medical cannabis. It also operates a network of health centers and satellite clinics under the ILANS and Zerenia brands; develops CBD-based cosmeceutical products under the Kuida brand name; and operates Zerenia clinic in Medellin and Peru. Khiron Life Sciences Corp. was incorporated in 2012 and is headquartered in Vancouver, Canada.